false 0001660334 0001660334 2024-08-30 2024-08-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 30, 2024

 

 

Verrica Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-38529   46-3137900

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

44 W. Gay St., Suite 400

West Chester, PA

   19380
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (484) 453-3300

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class

  

Trading

symbol

  

Name of each exchange

on which registered

Common Stock   VRCA   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Entry into Release Agreement and Consulting Agreement with Joe Bonaccorso

Consistent with Verrica Pharmaceuticals Inc.’s (the “Company”) previously disclosed expectations in its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on August 27, 2024 (the “Earlier Form 8-K”), on August 30, 2024, the Company and Joe Bonaccorso, the Company’s former Chief Commercial Officer, entered into a Release Agreement and a Consulting Agreement (each as defined in the Earlier Form 8-K). The Release Agreement and the Consulting Agreement are on the same terms as previously disclosed in the Earlier Form 8-K.

The description of the Release Agreement and the Consulting Agreement provided in the Earlier Form 8-K is not complete and is qualified in its entirety by reference to the Release Agreement and the Consulting Agreement, which the Company intends to file as exhibits to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Verrica Pharmaceuticals Inc.
Date: September 6, 2024      

/s/ P. Terence Kohler Jr.

      P. Terence Kohler Jr.
      Chief Financial Officer
v3.24.2.u1
Document and Entity Information
Aug. 30, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001660334
Document Type 8-K
Document Period End Date Aug. 30, 2024
Entity Registrant Name Verrica Pharmaceuticals Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38529
Entity Tax Identification Number 46-3137900
Entity Address, Address Line One 44 W. Gay St.
Entity Address, Address Line Two Suite 400
Entity Address, City or Town West Chester
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19380
City Area Code (484)
Local Phone Number 453-3300
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol VRCA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Verrica Parmaceuticals (NASDAQ:VRCA)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Verrica Parmaceuticals.
Verrica Parmaceuticals (NASDAQ:VRCA)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Verrica Parmaceuticals.